OTCPK:XVIP.F

Stock Analysis Report

Executive Summary

Xvivo Perfusion AB (publ), a medical technology company, provides solutions for organ, tissue, and cell preservation and perfusion in connection with transplantation.

Snowflake

Fundamentals

Flawless balance sheet with high growth potential.

Risks

  • Xvivo Perfusion is covered by less than 3 analysts.

Similar Companies

Share Price & News

How has Xvivo Perfusion's share price performed over time and what events caused price changes?


Latest Share Price and Events


Market Performance


7 Day Return

0%

OTCPK:XVIP.F

-0.9%

US Medical Equipment

1.3%

US Market


1 Year Return

-2.6%

OTCPK:XVIP.F

9.1%

US Medical Equipment

2.0%

US Market

XVIP.F underperformed the Medical Equipment industry which returned 8.7% over the past year.

XVIP.F underperformed the Market in United States of America which returned 1.7% over the past year.


Share holder returns

XVIP.FIndustryMarket
7 Day0%-0.9%1.3%
30 Day-7.0%0.7%3.9%
90 Dayn/a4.4%3.4%
1 Year-2.6%-2.6%10.0%9.1%4.2%2.0%
3 Year91.3%91.3%70.7%65.5%47.2%37.6%
5 Year173.6%173.6%130.7%104.3%60.5%42.9%

Price Volatility Vs. Market

How volatile is Xvivo Perfusion's share price compared to the market and industry in the last 5 years?


Simply Wall St News

No news available

Valuation

Is Xvivo Perfusion undervalued based on future cash flows and its price relative to the stock market?

633.95x

Price to Earnings (PE) ratio


Intrinsic Value Based on Future Cash Flows

Xvivo Perfusion's share price is above the future cash flow value, it's not available at a moderate discount (< 20%).

Xvivo Perfusion's share price is above the future cash flow value, it's not available at a substantial discount (< 40%).


Price Based on Earnings

Xvivo Perfusion is overvalued based on earnings compared to the US Medical Equipment industry average.

Xvivo Perfusion is overvalued based on earnings compared to the United States of America market.


Price Based on Expected Growth

Xvivo Perfusion is poor value based on expected growth next year.


Price Based on Value of Assets

Xvivo Perfusion is overvalued based on assets compared to the US Medical Equipment industry average.


Next Steps

Future Growth

How is Xvivo Perfusion expected to perform in the next 1 to 3 years based on estimates from 2 analysts?

83.9%

Forecasted annual earnings growth


Earnings and Revenue Growth Estimates


Future Annual Growth Analysis

Xvivo Perfusion's revenue is expected to grow significantly at over 20% yearly.

Xvivo Perfusion's earnings are expected to grow significantly at over 20% yearly.

Xvivo Perfusion's revenue growth is expected to exceed the United States of America market average.

Xvivo Perfusion's earnings growth is expected to exceed the United States of America market average.

Xvivo Perfusion's earnings growth is expected to exceed the low risk savings rate of 2.7%.


Earnings per Share Growth Estimates


Future Return on Equity

Xvivo Perfusion is not expected to efficiently use shareholders’ funds in the future (Return on Equity less than 20%).


Next Steps

Past Performance

How has Xvivo Perfusion performed over the past 5 years?

18.3%

Historical annual earnings growth


Earnings and Revenue History


Past Earnings Growth Analysis

Xvivo Perfusion's year on year earnings growth rate has been positive over the past 5 years.

Xvivo Perfusion's 1-year earnings growth is negative, it can't be compared to the 5-year average.

Xvivo Perfusion's 1-year earnings growth is negative, it can't be compared to the US Medical Equipment industry average.


Return on Equity

Xvivo Perfusion has not efficiently used shareholders’ funds last year (Return on Equity less than 20%).


Return on Assets

Xvivo Perfusion used its assets less efficiently than the US Medical Equipment industry average last year based on Return on Assets.


Return on Capital Employed

Xvivo Perfusion's use of capital deteriorated last year versus 3 years ago (Return on Capital Employed).


Next Steps

Financial Health

How is Xvivo Perfusion's financial position?


Financial Position Analysis

Xvivo Perfusion is able to meet its short term (1 year) commitments with its holdings of cash and other short term assets.

Xvivo Perfusion's cash and other short term assets cover its long term commitments.


Debt to Equity History and Analysis

Xvivo Perfusion's level of debt (1.3%) compared to net worth is satisfactory (less than 40%).

The level of debt compared to net worth has been reduced over the past 5 years (9.3% vs 1.3% today).

Debt is well covered by operating cash flow (309.9%, greater than 20% of total debt).

Interest payments on debt are well covered by earnings (EBIT is 8.1x coverage).


Balance Sheet

Low level of unsold assets.

Debt is covered by short term assets, assets are 40.9x debt.


Next Steps

Dividend

What is Xvivo Perfusion's current dividend yield, its reliability and sustainability?

0.20%

Expected Dividend Yield


Dividend Yield and Payments Analysis

Unable to evaluate Xvivo Perfusion's dividend yield against the bottom 25% of dividend payers as the company has not reported any payouts.

Unable to evaluate Xvivo Perfusion's dividend against the top 25% market benchmark as the company has not reported any payouts.

Unable to perform a dividend volatility check as Xvivo Perfusion has not reported any payouts.

Unable to verify if Xvivo Perfusion's dividend has been increasing as the company has not reported any payouts.


Current Payout to Shareholders

Unable to calculate sustainability of dividends as Xvivo Perfusion has not reported any payouts.


Future Payout to Shareholders

No need to calculate the sustainability of Xvivo Perfusion's dividends in 3 years as they are not expected to pay a notable one for United States of America.


Next Steps

Management

What is the CEO of Xvivo Perfusion's salary, the management and board of directors tenure and is there insider trading?

3.8yrs

Average management tenure


CEO

Magnus Nilsson (63yo)

8.7yrs

Tenure

0

Dr. Magnus Nilsson, Ph.D., has been the Chief Executive Officer and President of Xvivo Perfusion AB (publ) since 2011 and serves as its Managing Director. Dr. Nilsson served as the Chief Executive Officer  ...


CEO Compensation Analysis

Magnus's remuneration is lower than average for companies of similar size in United States of America.

Magnus's compensation has been consistent with company performance over the past year, both up more than 20%.


Management Age and Tenure

3.8yrs

Average Tenure

50yo

Average Age

The tenure for the Xvivo Perfusion management team is about average.


Board Age and Tenure

1.4yrs

Average Tenure

59.5yo

Average Age

The average tenure for the Xvivo Perfusion board of directors is less than 3 years, this suggests a new board.


Insider Trading

No 3 month open market individual insider trading information.


Recent Insider Transactions

Sellkr719,66408 Mar 19
Magnus Nilsson
EntityIndividual
Role
Chief Executive Officer
Chief Executive Officer & Managing Director
Shares37,567
Max Pricekr19.63

Ownership Breakdown


Management Team

  • Christer de Flon (70yo)

    Consultant

    • Tenure: 3.7yrs
  • Christoffer Rosenblad (44yo)

    CFO & Executive VP

    • Tenure: 7.7yrs
  • Magnus Nilsson (63yo)

    Chief Executive Officer & Managing Director

    • Tenure: 8.7yrs
  • Pär-Ola Larsson (50yo)

    Marketing and Sales Director of EMEA & Pacific

    • Tenure: 3.8yrs
  • Henrik Isaksson (48yo)

    Director of Operations

    • Tenure: 0.9yrs

Board Members

  • Gösta Johannesson (60yo)

    Chairman of the Board

    • Tenure: 1.4yrs
    • Compensation: kr205.00k
  • Dag Andresson (58yo)

    Director

    • Tenure: 0.4yrs
  • Camilla Öberg (55yo)

    Director

    • Tenure: 3.3yrs
    • Compensation: kr130.00k
  • Folke Nilsson (69yo)

    Director

    • Tenure: 0yrs
    • Compensation: kr130.00k
  • Yvonne Mårtensson (66yo)

    Director

    • Tenure: 1.4yrs
    • Compensation: kr130.00k
  • Alan Raffensperger (59yo)

    Director

    • Tenure: 1.4yrs
    • Compensation: kr130.00k

Company Information

Xvivo Perfusion AB (publ)'s company bio, employee growth, exchange listings and data sources


Key Information

  • Name: Xvivo Perfusion AB (publ)
  • Ticker: XVIP.F
  • Exchange: OTCPK
  • Founded: 1998
  • Industry: Health Care Equipment
  • Sector: Healthcare
  • Market Cap: kr4.405b
  • Listing Market Cap: kr458.634m
  • Shares outstanding: 26.60m
  • Website: https://www.xvivoperfusion.com

Number of Employees


Location

  • Xvivo Perfusion AB (publ)
  • Box 53015
  • Gothenburg
  • Västra Götaland County
  • 400 14
  • Sweden

Listings

TickerExchangePrimary SecuritySecurity TypeCountryCurrencyListed on
XVIVOOM (OMX Nordic Exchange Stockholm)YesShare CapitalSESEKOct 2012
XVIP.FOTCPK (Pink Sheets LLC)YesShare CapitalUSUSDOct 2012
0RKLLSE (London Stock Exchange)YesShare CapitalGBSEKOct 2012

Biography

Xvivo Perfusion AB (publ), a medical technology company, provides solutions for organ, tissue, and cell preservation and perfusion in connection with transplantation. The company offers XVIVO Perfusion Sys ...


Company Analysis and Financial Data Status

All financial data provided by Standard & Poor's Capital IQ.
DataLast Updated (UTC time)
Company Analysis2019/09/16 00:22
End of Day Share Price2019/09/03 00:00
Earnings2019/06/30
Annual Earnings2018/12/31


Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.